Navigation Links
Treatment for chemobrain may be possible

Cancer patients may rejoice as researchers have developed a treatment to treat// the condition called “chemobrain” in cancer survivors.

People who suffer from cancer and had to undergo chemotherapy often find the process of treatment affecting their mental functions and cognitive abilities. This condition is called chemobrain and some common symptoms are inability to concentrate, inability to be organized in doing daily activities, inability to think clearly and loss of memory.

Researchers from University of Cincinnati have discovered a possible treatment for this condition with the help of the drug dexmethyphenidate (d-MPH). The researchers report that the phase II study of the drug on the condition of chemobrain had been quite successful.

Researchers had reported that 154 cancer survivors in different medical centers have reported significant improvement in their conditions like lessening of fatigue, and increasing memory when treated with 10 mg to 50 mg of the drug d-MPH per day. All the participants of the study had completed four circles of chemotherapy when the drug d-MPH were prescribed and administered to them. Researchers confirmed that their study had shown the drug to be safe and effective to be prescribed to treat “chemobrain “ conditions to patients who need help.

The report was presented at the annual meeting of the American Society of Clinical Oncology this yar.
'"/>




Page: 1

Related medicine news :

1. Advances in Treatment of Cataracts
2. Recommendations for Treatment of Blood Pressue
3. Treatment for Menieres disease
4. Treatment for pre-menstrual syndrome is ineffective
5. Better Treatment for obesity
6. Gene Treatment for Heart Disease
7. More People Seeking Treatment for Depression
8. Focused Treatment For Childhood Cancer
9. Inadequate Drug Treatment For Youth
10. FDA Approves New surgery Treatment for Farsightedness
11. Treatment of antibiotics ineffectual in bronchitis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/23/2017)... (PRWEB) , ... May 23, 2017 , ... Therachat ... its new survey in an infographic on the current state of anxiety in support ... familiar with anxiety, was conducted in April 2017 and benchmarked general anxiety levels as ...
(Date:5/22/2017)... ... May 22, 2017 , ... Dr. Kiya Green, a ... periodontal plastic surgery treatments, including crown lengthening and gum reduction surgery, ... esthetic and functional procedures to help patients improve their oral health, reduce gummy ...
(Date:5/22/2017)... Galena, Alaska (PRWEB) , ... May 22, 2017 , ... ... town near the Arctic Circle made big headlines when it was targeted to build ... Low-Cost Energy in Bush Alaska,” former city manager Marvin L. Yoder describes the journey ...
(Date:5/21/2017)... ... , ... Chris Cornell, 52, was found dead on the night of Wednesday, May 17, 2017. ... singers in the rock industry would take his own life, but the extremely talented and ... illness played a role in the death of Chris Cornell . , Depression and ...
(Date:5/21/2017)... (PRWEB) , ... May 20, 2017 , ... Pot. Reefer. ... find it, review it, and share its attributes like never before. More than a ... to connect cannabis enthusiasts to stores, strains, products – and for the first time ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)... 22, 2017  As the specialty pharmacy industry ... to make the revolutionary shift from volume-based to ... ensuring positive patient outcomes and shaping the future ... focus away from clinical trials and toward data ... specialty drug therapy utilization in precise patient populations. ...
(Date:5/18/2017)... May 17, 2017  Bayer announced today that the ... be presented at the 53 rd Annual Meeting ... place June 2-6 in Chicago . ... span prostate, colorectal, liver and thyroid cancers, as well ... Phase II CHRONOS-1 trial of copanlisib in patients with ...
(Date:5/15/2017)... PHILADELPHIA , May 15, 2017 Enterin Inc., ... and developing novel compounds to treat Parkinson,s disease ... The study is a Phase 1/2a randomized, controlled, multicenter study ... sites. It will enroll 50 patients over a 9-to-12-month period. ... doses in 10 patients with PD. Participating sites include ...
Breaking Medicine Technology: